Apigenin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Apigenin dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Apigenin.
Dosing Protocols
Beginner Protocol — Sleep and Calm Support
Goal: Use apigenin for subjective sleep quality improvement or mild daytime calming through GABA-A receptor modulation, with minimal complexity and strong safety margin.
Protocol:
- Chamomile tea (Matricaria chamomilla) 1-2 cups 30-60 minutes before bedtime (primary approach)
- OR apigenin 50 mg 30-60 minutes before bedtime (supplement approach)
- Form: standardized chamomile tea OR apigenin 98% pure supplement from chamomile or parsley source
- Duration: ongoing nightly use as needed
Rationale: Chamomile tea has generations of safe use for sleep support and represents the most conservative entry to apigenin exposure. For users wanting higher dose without consuming multiple cups of tea, 50 mg apigenin supplementation provides approximately 30-50x the apigenin of a single cup of chamomile tea in one convenient dose. Doses at this level are unlikely to produce daytime sedation if taken in evening hours.
Optional additions:
- Magnesium bisglycinate 200-400 mg at bedtime (complementary GABAergic and muscle relaxation)
- L-theanine 100-200 mg at bedtime (complementary GABA modulation without melatonin-like sleep architecture effects)
- Glycine 1-3 grams at bedtime (amino acid sleep support)
Monitoring: Subjective sleep quality, sleep latency, number of awakenings, morning alertness. No specific laboratory monitoring required at this dose.
Expected timeline: Subjective effects often observed within days of consistent use. Full sleep pattern assessment requires 2-4 weeks of regular use.
Budget: Chamomile tea: $5-15/month. Apigenin 50 mg supplement: $15-30/month.
Intermediate Protocol — NAD+ Preservation Stack
Goal: Use apigenin as a CD38 inhibitor alongside NAD+ precursor supplementation to theoretically maximize NAD+ elevation and longevity-associated effects.
Protocol:
- Apigenin 100-250 mg once daily with breakfast
- Combined with NAD+ precursor: nicotinamide riboside 250-500 mg daily OR NMN 250-500 mg daily (pick one)
- Supporting background supplements:
- Pterostilbene 50-100 mg daily (sirtuin activator)
- Vitamin D3 2000-5000 IU daily
- Omega-3 fatty acids 2-3 grams EPA+DHA daily
Rationale: 100-250 mg daily apigenin provides meaningful CD38 inhibition based on preclinical pharmacokinetic data while remaining well below doses associated with clinically significant adverse effects. NAD+ precursor substrate + CD38 inhibitor combination targets both sides of NAD+ balance. Pterostilbene addition completes the SIRT1 activation story. Morning dosing avoids the subjective sedation that can occur with evening apigenin.
Monitoring: Annual comprehensive metabolic panel and complete blood count. Consider plasma NAD+ testing (available through some specialty laboratories) to document individual response. Blood pressure, fasting glucose, lipid panel as part of general health monitoring.
Expected timeline: Biomarker effects develop over 8-12 weeks of consistent supplementation. Subjective effects are less consistent.
Budget: Apigenin 100-250 mg: $25-50/month. NR or NMN: $40-80/month. Total stack: $100-200/month.
Advanced Protocol — Comprehensive Polyphenol Longevity Stack
Goal: Integrate apigenin into a comprehensive longevity and anti-inflammatory protocol alongside other polyphenols, NAD+ precursors, and supportive supplements.
Protocol:
- Apigenin 250-500 mg daily (split between breakfast and lunch for steady plasma levels)
- OR apigenin phytosome 100-200 mg daily (equivalent to higher-dose standard aglycone)
- Combined with comprehensive longevity stack:
- NAD+ precursor: NR 500-1000 mg daily OR NMN 500-1000 mg daily
- Pterostilbene 100-150 mg daily (sirtuin activator)
- Quercetin 500-1000 mg daily (broader flavonoid, mast cell stabilizer)
- Fisetin pulse: 1400 mg for 2 consecutive days monthly (senolytic)
- Curcumin phytosome 500-1000 mg daily (anti-inflammatory)
- Coenzyme Q10 200-400 mg daily (mitochondrial)
- Alpha-lipoic acid 300-600 mg daily (antioxidant)
- Vitamin D3 5000 IU daily (with K2 MK-7 100-200 mcg)
- Omega-3 3-4 grams EPA+DHA daily
Rationale: Higher apigenin doses approach therapeutic ranges used in some preclinical cancer studies while maintaining reasonable human safety margins. Phytosome formulation at lower dose achieves equivalent tissue levels. Comprehensive polyphenol stacking provides coverage across multiple mechanism classes.
Monitoring: Quarterly comprehensive metabolic panel, lipid panel, complete blood count, thyroid panel for first 6 months. Blood pressure, fasting glucose, HbA1c. Consider biological age clock testing (DNA methylation) to document integrated response. Plasma NAD+ and inflammatory markers (hs-CRP, IL-6) where accessible.
Expected timeline: Full stack effects develop over 6-18 months. Discontinuation can reveal which components produce subjective effects. Longevity-oriented benefits require long-term commitment.
Budget: $300-700/month depending on brand selection and prescription components.
Physician coordination: Advanced polyphenol protocols involving multiple concurrently-active CYP-modulating agents benefit from physician review, particularly if other pharmaceutical medications are involved. Specific concerns include warfarin dosing (multiple antiplatelet additives), thyroid function (at very high apigenin doses), and drug metabolism for narrow-therapeutic-index medications.
Adjustments for specific populations:
- Hormone-dependent cancer history: Use apigenin cautiously at modest doses (50-100 mg); consult oncology team.
- Anticoagulation therapy: Limit apigenin to 50-100 mg daily; physician communication.
- Sedative or benzodiazepine therapy: Avoid high-dose apigenin; stick to chamomile tea levels.
- Chamomile/ragweed allergy: Use synthetic or non-chamomile-source apigenin (parsley-derived, passionflower-derived); monitor for cross-reactivity.
- Pediatric or pregnancy/lactation: Limit to chamomile tea at conventional culinary doses; avoid high-dose supplementation.
Not applicable — apigenin is oral only. No injection, sublingual, intranasal, or topical formulations are established in research or commercial use for systemic applications.
Apigenin's oral availability, despite being moderate, is sufficient for most applications. Phytosome and liposomal formulations further enhance absorption. Topical apigenin formulations are explored preclinically for skin applications but are not commercially established.
Commonly Stacked With
Apigenin combines productively with multiple supplement classes in longevity, cognitive, sleep, and anti-inflammatory supplementation regimens.
Apigenin + nicotinamide riboside or NMN: This is the most mechanistically-compelling apigenin stack. Apigenin inhibits CD38 (the major NAD+-degrading enzyme) while NR or NMN provides NAD+ precursor substrate — the combination theoretically maximizes NAD+ elevation by simultaneously increasing substrate supply and decreasing degradation. Typical doses: apigenin 100-250 mg daily + NR 250-500 mg daily or NMN 250-500 mg daily. Take together with breakfast.
Apigenin + pterostilbene: Both polyphenols with longevity-oriented mechanisms; pterostilbene activates SIRT1 while apigenin preserves NAD+ substrate for SIRT1 activity. Reasonable pairing for comprehensive sirtuin-targeting. Typical doses: apigenin 100 mg + pterostilbene 50-100 mg daily.
Apigenin + quercetin: Both flavonoids with overlapping anti-inflammatory, mast cell stabilizing, and antioxidant activities. Apigenin adds CD38 inhibition and GABA-A modulation; quercetin adds stronger mast cell stabilization and stronger zinc ionophore activity. Reasonable combination for broad flavonoid coverage. Typical doses: apigenin 100-250 mg + quercetin 500 mg daily.
Apigenin + fisetin: Both natural polyphenols with complementary mechanisms. Apigenin for chronic daily CD38 inhibition and GABA-A effects; fisetin for intermittent senolytic pulse dosing. Typical protocol: apigenin 100-250 mg daily + fisetin 1400 mg for 2 consecutive days monthly (AFFIRM-LITE-adapted).
Apigenin + magnesium: Both support GABAergic signaling and sleep quality through complementary mechanisms. Magnesium bisglycinate 200-400 mg at bedtime + apigenin 50-100 mg 30-60 min before bed is a common sleep-supportive stack. Generally well-tolerated.
Apigenin + L-theanine: Both GABA-modulating compounds supporting relaxation without sedation. L-theanine 100-200 mg + apigenin 50-100 mg for calm focus. Reasonable pre-meeting or pre-stressful-event stack.
Apigenin + chamomile tea: Consuming chamomile tea alongside apigenin supplementation provides additional apigenin (with co-occurring flavonoids) in a traditional form. Modest synergy, primarily from the overall calming ritual.
Apigenin + curcumin: Both anti-inflammatory polyphenols with complementary mechanisms. Curcumin provides broader NF-kB and inflammatory pathway modulation; apigenin adds CD38-NAD+ preservation and GABA-A activity.
Apigenin + omega-3 fatty acids: Fish oil provides membrane EPA/DHA while apigenin protects polyunsaturated fatty acids from oxidation and provides complementary anti-inflammatory activity.
Apigenin + vitamin-c + other antioxidants: Apigenin's antioxidant regeneration activities benefit from presence of other antioxidants (vitamin C, vitamin E, selenium) in the overall nutrition. Balanced antioxidant stack.
Apigenin + berberine: Both compounds with mild AMPK activation; berberine more potent systemically. Combination reasonable for metabolic optimization with chronic daily dosing.
Sleep-supportive stack: Apigenin 50-100 mg + magnesium bisglycinate 300 mg + glycine 1-3 g + tart cherry extract 500 mg 30-60 minutes before bedtime. Generally well-tolerated sleep support without the concerns of pharmacological sleep agents.
Anxiety-reduction stack: Apigenin 100 mg + L-theanine 200 mg + ashwagandha (KSM-66) 300-600 mg. Generally well-tolerated anxiolytic-oriented stack.
Stacks to use cautiously:
- Apigenin + benzodiazepines: Theoretical additive GABA-A effects; avoid high-dose apigenin with pharmacological sedatives.
- Apigenin + anticoagulants (warfarin, DOACs): Theoretical enhanced bleeding risk; discuss with physician before high-dose supplementation.
- Apigenin + cyclosporine or tacrolimus: Potential CYP3A4 inhibition could increase drug levels; avoid or use with drug level monitoring.
- Apigenin + chemotherapy agents (tyrosine kinase inhibitors, some cytotoxics): Potential interactions via CYP and transporter modulation; discuss with oncology team.
- Apigenin + alcohol: Theoretical additive CNS depression at high doses of both; moderate alcohol with normal apigenin supplementation is reasonable.
Product selection notes:
- Standardized apigenin from parsley, chamomile, or passionflower extracts with >95% purity are preferred over lower-grade extracts.
- Apigenin phytosome or liposomal formulations provide 3-5x higher bioavailability versus standard aglycone — useful at lower doses or where tissue concentration matters.
- Avoid unverified-source apigenin; prefer products with third-party purity testing documentation.
- Chamomile tea remains a reasonable entry point for users seeking GABA-A-mediated calming without higher-dose supplementation.
Side Effects & Safety
Contraindications
**Absolute contraindications:** - **Known allergy to apigenin or Asteraceae family (chamomile, ragweed, daisy, chrysanthemum):** Cross-reactivity with these plant families is common; allergic individuals should avoid chamomile-source apigenin and use cautious introduction of parsley- or passionflower-source apigenin. - **Pregnancy (high-dose supplementation):** Safety data lacking; avoid pharmaceutical-dose apigenin. Dietary chamomile tea has traditional use during pregnancy but should be moderated. - **Lactation (high-dose supplementation):** Safety data lacking; avoid pharmaceutical-dose supplementation. **Relative contraindications (discuss with physician before use):** - **Anticoagulation therapy (warfarin, direct oral anticoagulants, clopidogrel):** Mild antiplatelet effects may improve bleeding risk at high supplementation doses; physician discussion recommended. - **Concurrent benzodiazepine or Z-drug therapy:** Theoretical additive GABA-A effects; avoid high-dose apigenin, limit to chamomile tea. - **Concurrent alcohol use (chronic heavy use):** Theoretical additive CNS depression at high doses of both; moderate with caution. - **Hormone-dependent cancer history (estrogen-receptor-positive breast cancer, endometrial cancer):** Weak phytoestrogen activity; consult oncology team before high-dose supplementation. - **Upcoming surgical procedures:** Discontinue apigenin 7-10 days before surgery to minimize bleeding risk. - **Concurrent chemotherapy (particularly tyrosine kinase inhibitors, some cytotoxic agents):** Potential drug interactions via CYP and transporter modulation; discuss with oncology team. - **Severe hepatic impairment:** Limited clinical data; theoretical concerns about altered metabolism. - **Cyclosporine, tacrolimus therapy:** Potential CYP3A4 inhibition could increase drug levels; avoid or use with drug level monitoring. **Caution populations:** - **Adults over 75 years:** Monitor for sedation or orthostatic effects; start at lower doses. - **Users with multiple polypharmacy agents:** Theoretical CYP modulation across multiple drug classes warrants physician awareness of supplementation. - **Users operating heavy machinery or driving:** Avoid higher apigenin doses during periods requiring alertness; preference for evening dosing. - **Chronic kidney or liver disease:** No specific dose adjustment documented but warrants clinical oversight. **Drug interactions requiring monitoring:** - Warfarin, DOACs (theoretical enhanced bleeding risk) - Benzodiazepines, Z-drugs (theoretical additive sedation) - Cyclosporine, tacrolimus (theoretical CYP3A4 inhibition) - Some chemotherapy agents (theoretical CYP modulation) - Antihypertensives (theoretical modest additive effects) - Aromatase inhibitor therapy (theoretical interference) **Discontinue immediately and seek medical attention if:** - Severe allergic reaction (rash, difficulty breathing, facial swelling) - Significant unexplained bleeding or bruising - Severe unexplained sedation or respiratory depression - Jaundice or severe abdominal pain suggestive of hepatic dysfunction
Additional Notes
Dose-response relationships: Apigenin's clinical effects span a wide range of doses depending on the target mechanism. GABA-A-mediated calming effects are produced at doses as low as 10-50 mg (chamomile tea range) and saturate at moderate doses. CD38 inhibition for NAD+ preservation requires higher doses (100-250 mg daily) based on preclinical pharmacokinetic data. Anti-inflammatory and anticancer effects have been studied at 500-1000 mg daily in preclinical and limited human contexts. Most commercial supplementation occurs in the 50-500 mg daily range.
Standard supplementation doses:
- Sleep and mild calming: 50-100 mg in the evening
- NAD+ preservation stack (with NR/NMN): 100-250 mg daily
- Anti-inflammatory and longevity stack: 250-500 mg daily
- Research and therapeutic investigational use: 500-1000 mg daily
Bioavailability considerations: Standard apigenin aglycone has approximately 20-25% oral bioavailability in rat studies. Human pharmacokinetic data are more limited but suggest similar relative bioavailability with some inter-individual variability. Apigenin phytosome formulations (lecithin complexes) provide 3-5x higher bioavailability, allowing equivalent tissue concentrations at lower doses. Liposomal apigenin provides further bioavailability enhancement for specialized applications. For most users, standard aglycone at higher oral doses is equally effective as phytosome at lower doses, with cost and tolerability driving the choice.
Timing: Apigenin's plasma half-life of approximately 90 minutes means plasma levels peak at 1-2 hours and decline substantially within 4-6 hours. For GABA-A applications (sleep, calming), evening dosing 30-60 minutes before bedtime provides maximum effect at the target time. For metabolic and anti-inflammatory applications, morning dosing with breakfast is appropriate. For higher-dose protocols, twice-daily dosing provides more sustained plasma levels than single daily dosing.
Food interaction: Apigenin's lipophilicity favors co-administration with meals containing some fat. Fasted administration reduces absorption approximately 30-40%. Gastrointestinal comfort is also better with food co-administration. Normal meals provide adequate lipid co-administration.
Storage: Apigenin is reasonably stable but benefits from storage away from direct light, heat, and moisture. Refrigeration is not required for most products; room-temperature cabinet storage is appropriate. Respect product expiration dates.
Quality verification: Prefer products specifying source (parsley, chamomile, passionflower), confirmed purity (>95%), and third-party testing documentation. Avoid products without clear sourcing or with inconsistent dosing claims. Synthetic apigenin and naturally-extracted apigenin are chemically identical; source preference is based primarily on purity standards and absence of co-contaminants.
Dosing for specific goals:
- Sleep support: 50-100 mg 30-60 min before bedtime
- Daytime calming: 25-50 mg in morning or as needed
- NAD+ preservation: 100-250 mg daily with breakfast (combined with NR or NMN)
- Comprehensive longevity stack: 250-500 mg daily split between breakfast and lunch
- Traditional chamomile use: 1-3 cups chamomile tea daily (provides 1-6 mg apigenin total)
Not recommended doses:
- Sustained daily doses above 1000 mg without specific clinical supervision
- High evening doses (>200 mg) during periods requiring alertness
- Pediatric doses (not established)
- Pregnancy/lactation supplementation (dietary chamomile is traditional, but pharmaceutical doses should be avoided)
Loading doses or cycling: No loading dose is required. Steady-state plasma levels are achieved within days of consistent dosing. Cycling (dose-free periods) is not necessary for most applications given apigenin's favorable safety profile and lack of tolerance development.
Special considerations for GABA-A effects: Apigenin's GABA-A activity produces only partial agonist effects without the full pharmacology of benzodiazepines. Tolerance development is minimal or absent at typical supplementation doses. Discontinuation does not produce withdrawal syndromes. Users can take apigenin nightly for sleep support for extended periods without expected loss of effect.
Frequently Asked Questions
What is the recommended Apigenin dosage?
Dosage for Apigenin varies by protocol. Consult a qualified healthcare provider.
How often should I take Apigenin?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Apigenin need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Apigenin side effects?
Apigenin is generally well-tolerated in both dietary and supplemental contexts. Common and uncommon adverse effects include: **Gastrointestinal effects (most common):** Mild nausea, bloating, or loose stools occur in a small percentage of users, typically mild and transient. Taking with food generally resolves symptoms. Severe gastrointestinal reactions are rare. **Sedation and drowsiness:** Apigenin's GABA-A activity can produce mild sedation, particularly at higher doses (500+ mg). Users should not operate heavy machinery or drive immediately after starting higher doses of apigenin supplementation. Chamomile tea rarely produces clinically significant sedation at culinary doses. **Headache:** Mild headache is reported occasionally, typically transient. **Chamomile allergic reactions:** Approximately 2-10% of adults have chamomile sensitization, usually presenting as contact dermatitis or allergic conjunctivitis. Systemic allergic reactions are rarer. Individuals with ragweed allergy, which shares cross-reactive proteins with chamomile, are at higher risk of chamomile sensitivity. Pure synthetic or isolated apigenin is less likely to produce allergic reactions than whole chamomile extracts because most chamomile allergens are proteins rather than small molecules. **Bleeding risk with anticoagulants:** Apigenin has mild antiplatelet activity and may theoretically enhance bleeding tendency in patients taking warfarin, clopidogrel, aspirin, or direct oral anticoagulants. Clinical significance at typical supplementation is likely modest but warrants awareness, particularly in polypharmacy contexts. Discontinue apigenin 7-10 days before surgical procedures. **Estrogenic activity (hormone-sensitive conditions):** Apigenin has weak phytoestrogen activity at high doses. Women with estrogen-dependent cancer history (breast, uterine) should consult their oncology team before supplementation. Clinical significance at culinary or modest supplementation doses is likely minimal. **Drug interactions through CYP enzyme modulation:** Apigenin can inhibit CYP1A2, CYP2C9, and CYP3A4 at high concentrations. Clinical relevance at typical oral supplementation is modest but theoretically could affect drugs with narrow therapeutic indices — warfarin, cyclosporine, tacrolimus, some chemotherapy agents. **Thyroid function interactions:** At high doses in animal models, apigenin has produced modest effects on thyroid hormone synthesis. Clinical significance in humans at typical supplementation doses has not been definitively characterized. **Pregnancy and lactation:** Apigenin safety during pregnancy has not been rigorously established in humans. Chamomile tea has traditional use during pregnancy but pharmaceutical doses are not recommended. Avoid high-dose apigenin supplementation during pregnancy or breastfeeding. **Pediatric use:** Pediatric safety and efficacy of purified apigenin have not been established. Chamomile tea is traditionally considered safe for children but pharmaceutical doses should be avoided. **Surgical considerations:** Due to antiplatelet and theoretical CYP effects, discontinue apigenin 7-10 days before surgical procedures. **Interactions with GABAergic medications:** Apigenin's GABA-A activity could theoretically enhance the effects of benzodiazepines, Z-drugs (zolpidem, zaleplon), alcohol, or other sedatives. Clinical significance at typical supplementation doses is modest but warrants caution. Avoid high-dose apigenin with benzodiazepines or sedative medications without physician guidance. **Allergic cross-reactivity:** Individuals with known Asteraceae family (daisy, ragweed, chrysanthemum) allergies should use chamomile and related apigenin sources cautiously. **Liver function:** Apigenin is not associated with hepatotoxicity at typical supplementation doses. Hepatic impairment does not typically require dose adjustment. **Long-term safety:** Dietary apigenin exposure has generational safe use data. Long-term (>1 year) purified apigenin supplementation data are less extensive but no major safety signals have emerged from available evidence. **Overall tolerability grade:** Excellent at culinary and modest supplementation doses. Generally good at higher doses (300-500 mg daily) with primary cautions being antiplatelet effects, sedation potential, and theoretical CYP interactions. No black-box-level safety concerns exist for healthy adults at typical supplementation.
Where can I buy Apigenin?
Visit our vendor directory to find trusted sources for Apigenin.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
